Now there’s a different way forward for biopharmaceutical companies to reach more patients
It is incredible to live in a time when there are so many life-changing treatments available. While these treatments are helping us live longer and often better than ever before, far too many patients still go undiagnosed and untreated. Healthcare needs to continue to focus our attention on identifying the right patients for the right treatments.
For today’s healthcare teams, the right diagnosis can often feel like searching for a needle in a haystack.
That is what makes the work we are doing for GE HealthCare’s Digital Pharma Solutions so compelling. Simply put, we’re focused on making things easier for healthcare teams, patients, and biopharma companies looking to reach more patients who may benefit from treatment.
We have a different way forward, where digital solutions play a significant role at critical points along the diagnostic care pathway.
To be clear, this is a difficult challenge to solve. There are nuances that drive the impact of these digital solutions – namely: scalability (who will have access to the solution?), training (who will know how to use the solution or interpret the results?) changes to workflow, and more.
With over 4 million devices in 160 countries and people in those countries to help guide clinician awareness and understanding, GE HealthCare is uniquely positioned to solve this challenge.
Plus, as a part of GE HealthCare, we’re already embedded across a wide breadth of diagnostic devices.
We can’t and don’t expect to do this alone.
We recognize the advancements that biopharma companies have made to accomplish similar goals and we want to work together to impact patient care. Our partners benefit from having digital solutions integrated directly into established clinical workflows and actionable insights.
Our proven expertise comes from decades of experience commercializing solutions within health systems. We have a proven methodology with full-scale deployment planning. And GE HealthCare tops the FDA list of AI enabled Medical devices authorized.1
We're living in a time of transformative innovation, and I feel privileged to contribute to bringing these advancements to those who need them most.
With our capabilities and your treatment innovation, we can advance precision care across the continuum from ECG, ultrasound, and imaging to cardiology, oncology, and beyond. Let’s get started.
* Data on File
References:
1. US Food and Drug Administration. Artificial Intelligence and Machine Learning (AI/ML)-Enabled Devices. October 19, 2023.
